Adagio Medical Stock
Adagio Medical is engaged in the research and development of treatments for cardiovascular diseases.
Sign up today and learn more about Adagio Medical Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Adagio Medical Stock
Adagio Medical is engaged in the research and development of treatments for cardiovascular diseases. Adagio Medical is committed to providing electrophysiologists innovative cryoablation catheters that create safe, continuous, transmural lesions to treat cardiac arrhythmias anywhere in the heart, including paroxysmal and persistent atrial fibrillation, atrial flutter, and ventricular tachycardia. The company was founded in 2011 and is based in Laguna Hills, California.
Funding History
| March 2013 | $2.5M |
|---|---|
| June 2013 | $3K |
| August 2014 | $4.1M |
| March 2019 | $7.0M |
| November 2020 | $42.5M |
Management
Founder, Chief Executive Officer and President
Olav Bergheim
CFO
Hugh A.Neuharth
Executive Director
Olav Bergheim
Vice, Marketing
Amit Agarwal
Vice President, Research & Development
Mehrzad Khakpour
Chief Operating Officer
Andrew Kirkpatrick
Vice President & General Counsel
Jacqueline Arnold Collins
Co-Founder
James Cox
Press
fiercebiotech - Feb, 21 2024
Arrhythmia ablation tech maker Adagio Medical picks up the tempo with $128M SPAC dealprnewswire - Feb, 16 2024
Adagio Medical To List on Nasdaq Through Business Combination with ARYA Sciences Acquisition Corp IV, Enabling ...seekingalpha - Feb, 16 2024
Adagio Medical to go public in $113M deal with SPAC ARYA Sciencesocbj - Dec, 1 2020
Adagio Medical Scores $42M for Heart Devicebioworld - Nov, 17 2020
Adagio Medical secures $42.5M in series E fundingEquityZen Recognized As:
